«Post-COVID syndrome»: neurological manifestations and treatment with the Ukrainian drug Cognum

The article considers the features of viral lesions during the COVID-19 pandemic and the pathogenetic rationale for the use of the drug Cognum in the treatment of neurological complications after the disease.

References:

1. Zupanets I.A., Golubovska O.A., Shkurba A.V. et al. (2020) Prospects for studying the use of quercetin in the treatment of COVID-9. UMJ, 136: 75–78. (In Ukr.).
2. Shirobokov V.P. (2020) Coronavirus and other emergent infections. UMJ, 136: 31–33. (In Ukr.)
3. Voznyuk I.A., Ilyina O.M., Kolomentsev S.V. (2020) Ischemic stroke as a clinical form and pathogenetic model in the structure of lesions of the central nervous system in COVID-19. Restore Med. Bull. , 4(98): 91–98. (In Rus.).
4. Pilotto A., Masciocchi S., Volonghi I. et al. (2020) The clinical spectrum of encephalitis in COVID-19 disease: the ENCOVID multicentre studi. doi:https://doi.org/10.1101/2020.06.19.20133991.
5. Andreev V.V., Podunov A.Yu., Lapin D.S. et al. (2020) Clinical and pathogenetic features of cerebral stroke in patients with novel coronavirus infection (COVID-19). Regional blood circulation and microcirculation, 19(3): 46–56. (In Rus.).
6. Boyarchuk O.D., Vinogradov O.O. (2013) Biochemistry of stress. SI «Taras Shevchenko National University», Luhansk, 69 р. (In Ukr.).
7. Burchinsky S.G. (2015) GABAergic agents in the pharmacotherapy of chronic cerebral ischemia. Int. Neurol. J., 1(71): 101–105. (In Rus.).
8. Evtushenko S.K., Sukhonosova O.Yu., Salnikova V.A. (2015) Experience of using the drug Cognum in children with functional and organic diseases of the nervous system of various etiologies. Int. Neurol. J., 5(75): 41–45. (In Rus.).